The decision to trial INE was informed by data suggesting that despite rituximab B cell depletion, some pemphigus patients experience reconstitution of CD19+ anti-Dsg autoreactive memory B cells, leading to relapse or recalcitrant disease.2 This evidence concerns the gene CD19 and pemphigus.